Prurigo Nodularis Treatment Market (By Product Type: Antihistamines, Capsaicin Cream, Corticosteroids, Emollients, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global prurigo nodularis treatment market size was valued at USD 2.13 billion in 2023 and is anticipated to reach around USD 3.17 billion by 2033, growing at a CAGR of 4.03% from 2024 to 2033. The use of prurigo nodularis treatment helps to stop flattening skin lesions, and the itch-scratch cycle, and reduces systematic or topical therapies, skin scratching and irritation, and itchiness directly.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. prurigo nodularis treatment market size reached USD 650 million in 2023 and is predicted to be worth around USD 980 million by 2033, at a CAGR of 4.19% from 2024 to 2033.
North America dominated the market in 2023. The increasing senior population leads to prurigo nodularis conditions and demand for prurigo nodularis treatment in the North American region. Particularly in the senior population, there is high prurigo nodularis seen. For the treatment of senior patients with serious prurigo nodularis, the Dupixent was authorized by Health Canada. These factors help to the growth of the prurigo nodularis treatment market in the North American Region.
Asia Pacific is estimated to be the fastest-growing during the forecast period of 2024-2033. India and China are the leading countries in the North American region for prurigo nodularis treatment. Prurigo nodularis may be higher in India, but there is a lack of published evidence. In India, there is an increase in dermatophytosis, which is a major cause of prurigo nodularis treatment. In India, prurigo nodularis homeopathy treatments are present. These factors help the growth of the prurigo nodularis treatment market in the Asia Pacific region.
The Asia Pacific prurigo nodularis treatment market size was calculated at USD 550 million in 2023 and is projected to expand around USD 840 million by 2033, poised to grow at a CAGR of 4.32% from 2024 to 2033.
Year | Market Size (USD Million) |
2023 | 550 |
2024 | 580 |
2025 | 600 |
2026 | 620 |
2027 | 650 |
2028 | 680 |
2029 | 700 |
2030 | 730 |
2031 | 760 |
2032 | 790 |
2033 | 840 |
Prurigo nodularis is a chronic skin condition characterized by intensely itchy nodules or bumps. The prurigo nodularis treatment market deals with pharmacies for treatment options, including phototherapy, systematic medications, antihistamines, capsaicin creams, immune modulators, and topical steroids. These treatments include topical medicines such as nonsteroids or corticosteroids, and anti-inflammatory medicines may be used to apply to itchy spots. Injectable medications like corticosteroids may be directly injected into the affected areas.
In cryotherapy, freezing temperatures are applied to the skin, which helps reduce nodules and itching. Topical medications have some benefits, such as easy application and removal, irritant effects, solvent properties, penetrability, and stability. This prurigo nodularis treatment is useful, especially in emergencies like during childbirth and allergic reactions. These factors help the growth of the market.
Report Coverage | Details |
Prurigo Nodularis Treatment Market Size in 2023 | USD 2.13 Billion |
Prurigo Nodularis Treatment Market Size in 2024 | USD 2.22 Billion |
Prurigo Nodularis Treatment Market Size by 2033 | USD 3.17 Billion |
Growth Rate from 2024 to 2033 | CAGR of 4.03% |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | By Product Type and By Distribution Channel |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver: Increased skin infection diseases
Rising skin infection diseases lead to the growth of the market. These skin infections occur due to microbes, bacteria, and other viruses that enter the body and start to multiply. A changed lifestyle is also the reason for infectious diseases. Prurigo nodularis treatment helps to stop itching and can heal the skin. This treatment includes an emollient that is applied to the skin, and it can reduce scratching. This is also helpful for flattening and softening the patches and bumps. The use of intralesional or topical steroids helps to treat prurigo nodularis. The use of systematic immunosuppressives or phototherapy helps the treatment of prurigo nodularis and helps the growth of the prurigo nodularis treatment market.
Restraint: Side effects of prurigo nodularis treatment
Prurigo nodularis treatment has some challenges, including the severity of prurigo nodularis, comorbidities, patient age, quality of life, and some side effects. Patients may be frustrated by the lack of improvement. By using the medications, neurological and gastrointestinal side effects are observed commonly. A large number of patients experience the adverse side effects of peripheral neuropathy. In severe and recalcitrant cases of prurigo nodularis, treatment shows some significant side effects, including hypercoagulability, neuropathy, fatigue, and teratogenicity.
The use of systematic antihistamines for prurigo nodularis treatment can cause some side effects, including arrhythmias, tachycardia, dysuria, constipation, dry mouth, impaired cognitive functions, hyperexcitability, and sedation. The use of some systematic immunosuppressives can cause adverse side effects, including transaminitis, gastrointestinal symptoms, and nausea. These side effects factors can restrict the growth of the prurigo nodularis treatment market.
Opportunity: Research and development
Prurigo nodularis treatment has some side effects, and to overcome these effects, the development of medications with no side effects is necessary. Investment in research and development is necessary to help the growth of the market. Use of the biological treatments for the prurigo nodularis. Use of dupilumab as a biological treatment in medications for prurigo nodularis. The development of new targeted therapeutics for prurigo nodularis and prevention from other conditions, such as CKD or tuberculosis, HIV, hepatitis C, and hepatitis B. In some cases, topical treatments or injections are not effective, and there is a need for advanced therapies. Advanced therapies can be developed to overcome prurigo nodularis. These factors help the growth of the prurigo nodularis treatment market.
The corticosteroids segment dominated the market in 2023. The corticosteroid is the first-line treatment for prurigo nodularis, and it is used in the form of injections. The corticosteroids are anti-inflammatory drugs that are used to reduce inflammation and may help to reduce itching, pain, and redness right away. Intralesional corticosteroids, normally triamcinolone acetonide treatment, are generally used for the treatment of nodularis. Its low concentration may be effective, but a high concentration is needed to treat the scarred pruriginous lesions. Topical corticosteroid is a mainstay for the prurigo nodularis treatment. It is highly effective in reducing itching and may help to take away nodules.
Corticosteroid is used in medical tape for coating, which can relieve itching. To prevent scratching, it serves as a protective barrier, and it helps in flattening bumps. These topical corticosteroids can be used for about two weeks. These factors help the growth of the corticosteroids segment and contribute to the growth of the prurigo nodularis treatment market.
The antihistamines segment is expected to grow the fastest during the forecast period. Antihistamines are of two types sedating antihistamines and nonsedating antihistamines. Sedating antihistamines are used at bedtime, and non-sedating antihistamines are used in the daytime, which helps to relieve the itching due to prurigo nodularis. In topical treatments, antihistamine medications are directly applied to the skin in the form of ointments or skin. Calamine lotion is commonly used for relief from itching, and it is an antihistamine or anti-itching medication. These factors help the growth of the antihistamine segment and contribute to the growth of the prurigo nodularis treatment market.
The retail pharmacies segment dominated the prurigo nodularis treatment market in 2023. Increasing prurigo nodularis diseases leads to demand for lotions, ointments, and many other medications that are related to the prurigo nodularis treatment. Retail pharmacies are easily accessible and provide medications and services to customers at affordable prices. These retail pharmacy services include medication therapy management and medication dispensing activities. In retail pharmacy, when covered with the beneficiary filling a prescription, the retail pharmacy collects beneficiary coinsurance or copayment and distributes the drug from the checklist.
The retail pharmacy passes the copayments to the pharmacy benefit managers (PBM), who pay the pharmacy the cleared compensation. People benefit from health and wellness services that are available in retail pharmacies and have high brand loyalty and satisfaction levels. Retail pharmacies provide both generic and branded drugs. These factors help to the growth of the retail pharmacy segments and contribute to the growth of the market.
The online pharmacies segment is estimated to be the fastest-growing during the forecast period. Online pharmacies offer many benefits. Online pharmacies are easily accessible and convenient for online shopping for prescription medicines, with the individual advantage of prescriptions filled from a mobile device, laptop, or PC. Online pharmacy permits individuals to buy their medications discreetly at the door. Online pharmacies have the benefits of saving money and one-on-one consultations.
In the U.S., Canada, and the North American region, online pharmacies' growth is attributed to an increased number of Internet consumers and rising access to online and web-based services. These factors help the growth of the online pharmacy segment and contribute to the growth of the prurigo nodularis treatment market.
Segments Covered in the Report
By Product Type
By Distribution Channel
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Prurigo Nodularis Treatment Market
5.1. COVID-19 Landscape: Prurigo Nodularis Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Prurigo Nodularis Treatment Market, By Product Type
8.1. Prurigo Nodularis Treatment Market, by Product Type, 2024-2033
8.1.1. Antihistamines
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Capsaicin Cream
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Corticosteroids
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Emollients
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Prurigo Nodularis Treatment Market, By Distribution Channel
9.1. Prurigo Nodularis Treatment Market, by Distribution Channel, 2024-2033
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Prurigo Nodularis Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Product Type (2021-2033)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
Chapter 11. Company Profiles
11.1. Bayer AG
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Celgene Corporation
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Glaxo Smith Kline plc
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Galderma Takeda Pharmaceuticals (Nestle Skin Health Company)
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Johnson & Johnson Services Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Merk & Co. Inc
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Novartis AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Pfizer Inc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Sanofi SA
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Teva Pharmaceutical Industries Ltd
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client